🔗 Share this article

Chancellor Rachel Reeves has revealed she is planning "specific measures to tackle household expense challenges" in the upcoming financial statement.

In comments to media outlets, she stated that lowering price rises is a shared responsibility of both the government and the Bank of England.

The UK's price growth is expected to be the highest among the Group of Seven developed nations this year and next.

Potential Energy Cost Interventions

Sources suggest the government could take action to reduce energy bills, for instance by slashing the present 5% level of VAT applied on energy supplies.

A further option is to cut some of the policy costs presently added to household expenses.

Budgetary Constraints and Analyst Expectations

The administration will obtain the latest draft from the official forecaster, the OBR, on Monday, which will show how much space there is for such actions.

The view from most analysts is that the Chancellor will have to declare higher taxes or expenditure reductions in order to meet her declared debt limits.

Earlier on the same day, estimates suggested there was a £22bn deficit for the Treasury chief to resolve, which is at the lower end of forecasts.

"There's a joint job between the central bank and the administration to continue tackling some of the sources of inflation," the Chancellor told the BBC in Washington, at the conferences of the International Monetary Fund and global financial institution.

Tax Pledges and Global Concerns

While much of the attention has been on likely tax rises, the chancellor said the latest information from the fiscal watchdog had not changed her vow to election pledges not to raise tax levels on income tax, sales tax or social security contributions.

She attributed an "uncertain world" with rising international and trade issues for the Budget revenue measures, likely to be focused on those "with the broadest shoulders."

Global Economic Tensions

Commenting on concerns about the United Kingdom's trade ties with the Asian nation she said: "The UK's national security always take priority."

Last week's declaration by Chinese authorities to tighten trade restrictions on rare earths and other resources that are essential for high-technology production led American leader the US President to threaten an additional 100% import tax on goods from China, increasing the possibility of an all-out commercial conflict between the two global powers.

The US Treasury Secretary called the Chinese decision "commercial pressure" and "a international production control attempt."

Inquired about accepting the US offer to participate in its conflict with the Asian nation, the Chancellor said she was "very concerned" by China's actions and encouraged the Beijing authorities "not to put up barriers and restrict access."

She said the action was "damaging for the global economy and creates further obstacles."

"It is my opinion there are sectors where we need to address China, but there are also important prospects to trade with Chinese markets, including financial services and other areas of the economy. We've got to achieve that balance correct."

The Treasury chief also affirmed she was working with other major economies "regarding our own critical minerals plan, so that we are more independent."

NHS Drug Pricing and Investment

The Chancellor also acknowledged that the cost the National Health Service spends on drugs could increase as a consequence of ongoing discussions with the Trump administration and its pharmaceutical firms, in exchange for reduced taxes and capital.

A number of the world's largest pharmaceutical manufacturers have said in recent statements that they are either pausing or scrapping investments in the United Kingdom, with several blaming the insufficient payments they are getting.

Last month, the Science Minister said the price the health service pays for medicines would must rise to stop firms and pharmaceutical investment departing from the UK.

Reeves stated to the BBC: "It has been observed as a result of the cost structure, that clinical trials, recent pharmaceuticals have not been available in the United Kingdom in the manner that they are in other European countries."

"The objective is to make sure that individuals getting care from the National Health Service are can obtain the finest essential treatments in the globe. And so we are looking at this situation, and... looking to obtain additional investment into Britain."